These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27681114)

  • 1. Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin.
    Hirai K; Ishii H; Shimoshikiryo T; Shimomura T; Tsuji D; Inoue K; Kadoiri T; Itoh K
    Ther Drug Monit; 2016 Dec; 38(6):706-710. PubMed ID: 27681114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented Renal Clearance in Pediatric Patients With Febrile Neutropenia Associated With Vancomycin Clearance.
    Hirai K; Ihara S; Kinae A; Ikegaya K; Suzuki M; Hirano K; Itoh K
    Ther Drug Monit; 2016 Jun; 38(3):393-7. PubMed ID: 27172381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a Nomogram for Achieving Target Trough Concentration of Vancomycin: Accuracy in Patients With Augmented Renal Function.
    Ishii H; Hirai K; Sugiyama K; Nakatani E; Kimura M; Itoh K
    Ther Drug Monit; 2018 Dec; 40(6):693-698. PubMed ID: 30157096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Capping Creatinine Clearance on Achieving Therapeutic Vancomycin Concentrations in Neurocritically Ill Patients with Traumatic Brain Injury.
    Nelson NR; Morbitzer KA; Jordan JD; Rhoney DH
    Neurocrit Care; 2019 Feb; 30(1):126-131. PubMed ID: 30051194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.
    Yu YX; Lu J; Lu HD; Li L; Li JJ; Shi L; Duan LF; Zhuang ZW; Xue SD; Shen Y; Tang L
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e6-e14. PubMed ID: 33414258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin.
    Minkutė R; Briedis V; Steponavičiūtė R; Vitkauskienė A; Mačiulaitis R
    J Clin Pharm Ther; 2013 Dec; 38(6):462-7. PubMed ID: 23924288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of Augmented Renal Clearance in Trauma Intensive Care Scoring System to Improve Vancomycin Dosing in Trauma Patients at Risk for Augmented Renal Clearance.
    Molina KC; Hall ST; Barletta JF; Mangram AJ; Dzandu JK; Huang V
    Surg Infect (Larchmt); 2020 Feb; 21(1):43-47. PubMed ID: 31335259
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of renal clearance on vancomycin area under the concentration-time curve deviations in critically ill patients.
    Ishigo T; Ibe Y; Fujii S; Kazuma S; Aigami T; Kashiwagi Y; Takada R; Takahashi S; Fukudo M; Toda T
    J Infect Chemother; 2023 Aug; 29(8):769-777. PubMed ID: 37150254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients.
    Mikami R; Imai S; Hayakawa M; Sugawara M; Takekuma Y
    J Infect Chemother; 2022 Feb; 28(2):199-205. PubMed ID: 34686459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
    Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
    Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.
    Belabbas T; Yamada T; Egashira N; Hirota T; Suetsugu K; Mori Y; Kato K; Akashi K; Ieiri I
    J Infect Chemother; 2023 Apr; 29(4):391-400. PubMed ID: 36682608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of cerebral fluid drainage on the pharmacokinetics of vancomycin in neurosurgical patients.
    Ichie T; Urano K; Suzuki D; Okada T; Kobayashi N; Hayashi H; Sugiura Y; Yamamura K; Sugiyama T
    Pharmazie; 2015 Jun; 70(6):404-9. PubMed ID: 26189303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented renal clearance in septic patients and implications for vancomycin optimisation.
    Baptista JP; Sousa E; Martins PJ; Pimentel JM
    Int J Antimicrob Agents; 2012 May; 39(5):420-3. PubMed ID: 22386742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment.
    Tang L; Ding XY; Duan LF; Li L; Lu HD; Zhou F; Shi L; Lu J; Shen Y; Zhuang ZW; Sun JT; Zhou Q; Zhu CQ; Li JJ; Yu YX
    Front Pharmacol; 2021; 12():622948. PubMed ID: 34177564
    [No Abstract]   [Full Text] [Related]  

  • 15. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.
    Pea F; Porreca L; Baraldo M; Furlanut M
    J Antimicrob Chemother; 2000 Mar; 45(3):329-35. PubMed ID: 10702552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment].
    Campassi ML; Gonzalez MC; Masevicius FD; Vazquez AR; Moseinco M; Navarro NC; Previgliano L; Rubatto NP; Benites MH; Estenssoro E; Dubin A
    Rev Bras Ter Intensiva; 2014; 26(1):13-20. PubMed ID: 24770684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters.
    Teramachi H; Hatakeyama H; Matsushita R; Imai Y; Miyamoto K; Tsuji A
    Biol Pharm Bull; 2002 Oct; 25(10):1333-8. PubMed ID: 12392090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods.
    Tsuji Y; Hiraki Y; Mizoguchi A; Sadoh S; Sonemoto E; Kamimura H; Karube Y
    J Clin Pharm Ther; 2009 Aug; 34(4):465-72. PubMed ID: 19583680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer.
    AbuSara AK; Abdelrahman DH; Habash KI; Al-Shaer MH; Le J; Nazer LH
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00912. PubMed ID: 34990089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian estimation of pharmacokinetic parameters of vancomycin in patients with decreasing renal function.
    Yamamoto T; Terakawa H; Hisaka A; Suzuki H
    J Pharm Sci; 2012 Aug; 101(8):2968-75. PubMed ID: 22570265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.